Clinical Trials Browser

Phase 1/2 × Active not recruiting × Neuroblastoma × Clear all

NCT01757626 2026-01-07

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Phase 1/2 Active not recruiting

186 enrolled 2 FDA

CNS

Neuroblastoma

NCT02650401 2025-12-24

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT01192555 2025-08-01

ATOMIC

Phase 1/2 Active not recruiting

11 enrolled

CNS

Neuroblastoma

NCT00911560 2025-06-05

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Phase 1/2 Active not recruiting

374 enrolled

CNS

Neuroblastoma

NCT03373097 2025-02-05

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Phase 1/2 Active not recruiting

42 enrolled

CNSSarcoma

Neuroblastoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma